Today's News |
VoxCell BioInnovation Wins 'Women-Led Impact Investor Challenge', Takes Home $100,000 Prize
Monday, December 12, 2022
Vancouver, BC, December 12, 2022--(T-Net)--VoxCell BioInnovation announced that it has won the Women-led Impact Investor Challenge and a prize of $100,000.
The Impact Investor Challenge is a comprehensive, 11-week program for:
Spring Activator facilitates a cohort of impact ventures and a cohort of impact-curious investors, in navigating the fundraising process. This is done through a combination of weekly sessions, pitch events and networking opportunities.
At the end of the program, the investor cohort collectively awards $100,000* in investments to their top chosen company from the entrepreneur cohort.
The company's CEO & CSO Dr. Karolina Valente presented at the challenge and showcasing their products.
VoxCell BioInnovation is creating fully vascularized, human-like cancer tissue models by combining a custom high-resolution 3D bioprinter, advanced vascularization software, and proprietary bioinks.
VoxCell aims to accelerate the development of life-saving anti-cancer drugs by providing tissue models that can identify inviable candidates earlier in the drug-development pipeline.
Dr. Karolina Valente, CEO & CSO, VoxCell BioInnovation Inc.
About VoxCell BioInnovation
Human-Like Tissue
Utilizing a passionate and talented team, VoxCell is providing an extraordinary line of human-like tissue solutions for the drug development industry and the field of Oncology research by creating 3D vascularized cancer tissue models. Our 3D Bioprinter uses a state of the art laser with a process that crosslinks bioink with extreme precision, producing incredible high resolution 3D bioprinted tissues. Combined with our proprietary software, we are able to print tissues with vasculature for more meaningful in vitro testing. This process occurs only at the focal point of the laser (the voxel, hence VoxCell), allowing for printing anywhere in the polymer, including within structures, unlike traditional extrusion based 3D bioprinters.
Our tissue models will increase confidence in new drug candidates, decrease the failure rate (currently more than 95% of drugs in the pipeline fail), and impact the speed for new therapies to get to market. The successful translation between pre-clinical trial data and clinical trial results is less than 8% and we are on a mission to change that.
Testing on human-like tissues will provide better data to identify and eliminate unsuccessful drug candidates sooner, increasing the throughput and reducing the volume and cost of animal and human testing, ultimately getting life saving therapies to market and in the hands of people who need them sooner.
Learn more about VoxCell BioInnovation Inc.
About SPRING Activator
Spring empowers entrepreneurs, investors, and entrepreneurial ecosystem organizations to change the world through innovation. https://spring.is/